Amphastar Pharmaceuticals (AMPH) Change in Accured Expenses (2013 - 2026)

Amphastar Pharmaceuticals' Change in Accured Expenses history runs 14 years deep, the most recent figure standing at $9.6 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 45.45% year-over-year to $9.6 million in Q1 2026; TTM through Mar 2026 was -$12.6 million, a 121.62% decrease from a year earlier, with the FY2025 full-year figure at -$4.6 million, down 107.17% from the prior year.
• Change in Accured Expenses advanced to $9.6 million in Q1 2026 per AMPH's latest filing, from -$42.6 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $25.3 million in Q3 2025 and bottomed at -$42.6 million in Q4 2025.
• The 5-year median for Change in Accured Expenses is $5.5 million (2023), against an average of $4.8 million.
• Across the five-year window, Change in Accured Expenses surged 2803.38% in 2023 and plunged 2119.13% in 2025, its largest moves.
• Year by year, Change in Accured Expenses stood at -$13.6 million in 2022, then soared by 75.06% to -$3.4 million in 2023, then soared by 162.34% to $2.1 million in 2024, then plunged by 2119.13% to -$42.6 million in 2025, then jumped by 122.52% to $9.6 million in 2026.
• Per Business Quant, the three latest AMPH Change in Accured Expenses figures stand at $9.6 million (Q1 2026), -$42.6 million (Q4 2025), and $25.3 million (Q3 2025).